In the present study, SCIN has been identified as a new prognostic biomarker and associated with MMP2/9 expression and tumor immune infiltration in gliomas, which indicates that SCIN may be used as a target for glioma treatment. This evidence concerns the gene SCIN and central nervous system cancer.